PlasmaTech Announces $14.0 M Public Offering and NASDAQ Listing
New York, NY – December 24, 2014 – Press Release: New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm represented H.C. Wainwright & Co. and Aegis Capital Corp. as underwriters in PlasmaTech Biopharmaceuticals, Inc.’s public offering of 3,500,000 shares of common stock and 3,500,000 warrants. The gross proceeds from the offering were $14,035,000 and the offering price was $4.00 per share and $.01 per warrant. The warrants have a per share exercise price of $5.00 and are exercisable immediately. PlasmaTech common stock and warrants began trading on the NASDAQ Capital Market (effective December 19, 2014) under the symbols “PTBI” and “PTBIW” respectively.
PlasmaTech Biopharmaceuticals, Inc. is a biopharmaceutical company focused on advanced targeted treatments for critical patient care. The Sichenzia Ross Friedman Ference LLP team was led by Partners Jeffrey J. Fessler and Marcelle Balcombe.
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $7.7 Million Overnight Bought Offering of Cel-Sci Common Stock - March 26, 2020
- Coronavirus (Covid 19) Update - March 16, 2020
- Founding Partner Gregory Sichenzia Featured in Law360 Article on Coronavirus-fueled Market Volatility - March 10, 2020